Skip to content
Abierto

Vendor, Paris 8, FRA

Osivax

UEI M4YDKJJRJYC7, CAGE FBDR2

2 awards and $20,229,361 obligated between July 25, 2025 and September 14, 2026, 100% under full and open competition, against 1.0 offers on average where reported. 3 of the awards trace back to a SAM.gov solicitation on this site.

Sells to

Awarding agencies by dollars.

Office of Assistant Secretary for Preparedness and Response$20,229,361

Industries

NAICS on the awards, by dollars.

Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714$20,229,361

How it wins

Awards by competition, set-aside and type.

Full and Open Competition2
Definitive Contract2

Solicitations it won

SAM.gov opportunities whose award USAspending attributes to this vendor.

Awards

Every award in the window, by dollars obligated.

ContractAwarding officeDescribed asObligated
75A50125C00008Definitive Contract, July 25, 2025, Full and Open Competition, 1 offersSolicitation Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and ResponseOsivax - Clinical Proof of Concept of OVX836, a Single-Shot Broadly Protective Influenza a Vaccine for Immediate Protection Against EmergingNAICS 541714, PSC AN11$19,485,392
75A50125C00006Definitive Contract, September 19, 2025, Full and Open Competition, 1 offersBarda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and ResponseOxivax - Aoi #28: Influenza Vaccine Innovation. Advancing Metagenomic Next-Generation Sequencing Based Agnostic Diagnostics for Viral PathogNAICS 541714, PSC AN14$743,969
Transactions
6 across 2 awards